SCHEMBL1267553

SCHEMBL1267553

Cc1cc(Nc2c(C(=O)N3CCCC3CO)sc3c2ccc(=O)n3-c2ccccc2Cl)ccc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.37
HRH3 Q9Y5N1 1/20 0.36
CHRNA7 P36544 1/20 0.34
DHODH Q02127 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
TDP1 Q9NUW8 2/20 0.33
NTRK1 P04629 2/20 0.33
EGFR P00533 1/20 0.33
MAPT P10636 2/20 0.32
HSD17B10 Q99714 1/20 0.32
GRM5 P41594 1/20 0.32
CHRM2 P08172 2/20 0.32
CHRM4 P08173 2/20 0.32
CHRM1 P11229 2/20 0.32
CHRM3 P20309 2/20 0.32
ADORA3 P0DMS8 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
PDK2 Q15119 1/20 0.32
MCHR1 Q99705 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1267550 1.00 RAB9A (0.37) RAB9AHRH3CHRNA7DHODHRXFP1
SCHEMBL1266088 0.90 RAB9A (0.39) RAB9AHRH3TDP1NTRK1PDK2
SCHEMBL1267338 0.90 RAB9A (0.39) RAB9AHRH3TDP1NTRK1PDK2
SCHEMBL3829840 0.90 RAB9A (0.39) RAB9AHRH3TDP1NTRK1PDK2
SCHEMBL1265830 0.89 RAB9A (0.37) RAB9AHRH3TDP1EGFRGRM5
SCHEMBL1266647 0.87 P2RX3 (0.33) HRH3CHRNA7DHODHRXFP1MAPT
SCHEMBL1267431 0.87 RAB9A (0.37) RAB9AHRH3TDP1MAPT
SCHEMBL1267051 0.87 RAB9A (0.37) RAB9AHRH3TDP1MAPTADORA3
SCHEMBL1267214 0.86 RAB9A (0.39) RAB9AHRH3TDP1
SCHEMBL1266746 0.86 RAB9A (0.39) RAB9AHRH3TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034495-A1 Method of Modulating Stress-Activated Protein Kinase System INTERMUNE, INC. (US) 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034495-A1 Method of Modulating Stress-Activated Protein Kinase System MAPKAPK2, MAP3K6, MAP3K2 RAB9A 2993/4885HRH3 1577/4885CHRNA7 3397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.